KEYBIOME INC

Biotech · Private

AimA, a recombinant anti-inflammatory protein therapeutic that modulates intestinal neutrophils and dysbiotic microbiomes in inflammatory bowel disease

Grants
$228K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Aim protein-based anti-inflammatory therapeutic for the treatment of IBD$1
Federal grantDepartment of Health and Human Services · Phase I · Aim protein-based anti-inflammatory therapeutic for the treatment of IBD$228,408
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2045Tango Biosciences Inc.——
2046AVIARA PHARMACEUTICALS, INC.——
2047BLR BIO, LLC——
2048KEYBIOME INC——
2049Seven Bridges Capital LLC—$1.0M
2050SAMDI TECH, INC.——
2051CORD BLOOD PLUS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.